Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-08
2009-11-03
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S087000, C424S001850, C424S001810
Reexamination Certificate
active
07612206
ABSTRACT:
Novel benzamide compounds of Formula (I), Formula (II), and Formula (III), salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A method for diagnosing a mammal for the presence of a mammalian tumor therein comprises administering to the mammal a diagnostic imaging detectable effective amount of a benzamide compound having a structure illustrated in Formula (I), Formula (II) and Formula (III) and detecting binding of the compound to a tumor in the mammal. A method for diagnostic imaging of a mammalian tissue having cell surface sigma-2 receptors comprising administering to a mammal a diagnostic imaging amount of a compound having a structure illustrated in Formula (I) Formula (II) and Formula (III) and detecting an image of a tissue having an ample cells with sigma-2 receptors.
REFERENCES:
patent: 6046210 (2000-04-01), Stemp
patent: 6113877 (2000-09-01), Mach
patent: 6447748 (2002-09-01), John
patent: 7390902 (2008-06-01), Mach et al.
patent: 2005/0107398 (2005-05-01), Mach et al.
patent: 2008/0161343 (2008-07-01), Mach et al.
patent: 2005048810 (2005-06-01), None
International Search Report in the related application PCT/U808/655555 issued on Mar. 3, 2009.
International Search Report—PCT/U504/25304—Jun. 27, 2005.
Al-Nabulsi I, et al, Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells, Br. J. Cancer, 1999, p. 925-33, vol. 81(6).
Anderson CJ and Welch MJ, Radiometal-labeled agents (non-technetium) for diagnostic imaging, Chem. Rev., 1999, p. 2219-34, vol. 99(9).
Berardi F, et al, 4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity, J. Med. Chem., 2004, p. 2308-17, vol. 47(9).
Bonhaus DW, et al., [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus, J. Pharmacol. Exp. Ther., 1993, p. 961-70, vol. 267(2).
Bowen WD, et al, CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity, Eur. J. Pharmacol., 1995, p. 257-60, vol. 278(3).
Colabufo NA, et al, Distribution of sigma receptors in EMT-6 cells: preliminary biological evaluation of PB167 and potential for in-vivo PET, J. Pharm. Pharmacol., 2005, p. 1453-9, vol. 57(11).
Hou CT, et al, Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker, Nucl. Med. Biol., 2006, p. 203-9, vol. 33(2).
Huang Y, et al, Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands, J. Med. Chem., 2001, p. 1815-26, vol. 44(11).
Jurisson SS and Lydon JD, Potential technetium small molecule radiopharmaceuticals, Chem. Rev., 1999, p. 2205-18, vol. 99(9).
Kassiou M, et al, Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors, Bioorg. Med. Chem., 2005, p. 3623-6, vol. 13(11).
Mach RH, et al, Sigma 2 receptors as potential biomarkers of proliferation in breast cancer, Cancer Res., 1997, p. 156-61, vol. 57(1).
Mach RH, et al, Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors, Bioorg. Med. Chem., 2003, p. 225-33, vol. 11(2).
Mach RH, et al, Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands, Bioorg. Med. Chem. Lett., 2004, p. 195-202, vol. 14(1).
Tu Z, et al, Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer, Nucl. Med. Biol., 2005, p. 423-30, vol. 35(5).
Wheeler KT, et al, Sigma-2 receptors as a biomarker of proliferation in solid tumours, Br. J. Cancer, 2000, p. 1223-32, vol. 82(6).
Xu J, et al, [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe, Eur. J. Pharmacol., 2005, p. 8-17, vol. 525(1-3).
Supplementary Partial European Search Report issued on Oct. 10, 2008, in related application 04817745.5.
Curtet et al, New arylpiperazine derivatives as antagonists of the human cloned 5-HT4 receptor isoforms, J Med Chem, 2000, 43:3761-3769.
Hackling et al, N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands, J Med Chem, 2003, 46:3883-3899.
Leopoldo et al, Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]aryl carboxamides as potent and selective dopamine D3 receptor ligands, J Med Chem, 2002, 45:5727-5735.
Mach Robert
Rowland Douglas J.
Tu Zhude
Welch Michael J.
Chandrakumar Nizal S
Seaman D. Margaret
Sonnenschein Nath and Rosenthal LLP
Washington University
LandOfFree
Sigma-2 receptor radiotracers for imaging the proliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sigma-2 receptor radiotracers for imaging the proliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sigma-2 receptor radiotracers for imaging the proliferative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143862